Infektionen und Infektions-prävention bei Multipler Sklerose

A. Winkelmann; M. Löbermann; E. C. Reisinger; U. K. Zettl

doi:10.1055/s-0038-1627755

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2014; 33(12): 883-890
DOI: 10.1055/s-0038-1627755

Multiple Sklerose

Schattauer GmbH

Infektionen und Infektions-prävention bei Multipler Sklerose

Fragen und Antworten für die klinische PraxisInfections and prevention of infections in patients with multiple sclerosis

A. Winkelmann^*

¹Klinik und Poliklinik für Neurologie, Universität Rostock

,

M. Löbermann^*

²Zentrum für Innere Medizin, Klinik und Poliklinik für Innere Medizin II, Abteilung für Tropenmedizin, Infektionskrankheiten und Nephrologie, Universität Rostock

,

E. C. Reisinger

²Zentrum für Innere Medizin, Klinik und Poliklinik für Innere Medizin II, Abteilung für Tropenmedizin, Infektionskrankheiten und Nephrologie, Universität Rostock

,

U. K. Zettl

¹Klinik und Poliklinik für Neurologie, Universität Rostock

› Institutsangaben

Abstract

Zusammenfassung

Der Artikel geht einleitend auf ätiopathologische Aspekte von Infektionen im Rahmen der Multiplen Sklerose (MS) ein. Nachfolgend werden infektiologische Risiken und Komplikationen im Zusammenhang mit immunmodulierenden MS-Therapeutika unter besonderer Berücksichtigung neu verfügbarer Behandlungsoptionen zusammengefasst und Empfehlungen zur Infektionsprävention unter diesen Therapien gegeben. Abschließend erfolgt die Diskussion folgender klinisch relevanter Probleme: generelle Impfempfehlung, Sicherheit von Impfungen und Kontrolle des Impferfolges bei MS.

Summary

We initially discuss aetiological and pathological aspects of infections in the context of multiple sclerosis. Disease modifying treatment can be associated with serious infections. Relevant issues concerning prevention and management of treatment associated infections with special focus on newly available treatment options are summarized. To address clinical relevant topics, general vaccine recommendations are adapted to compile with safety and efficacy in patients with multiple sclerosis.

Schlüsselwörter

Multiple Sklerose - Infektionen - Immuntherapien - Impfungen

Keywords

Multiple sclerosis - infections - disease modifying treatment - vaccinations

Volltext

Referenzen

Literatur
1 Mix E. et al. Animal models of multiple sclerosis – potentials and limitations. Prog Neurobiol 2010; 92 (03) 386-404.
2 Baranzini SE. et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010; 464 7293 1351-6.
3 Dyment DA. et al. Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. J Neurol Neuro surg Psychiatry 2006; 77 (02) 258-9.
4 Sawcer S. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476 7359 214-9.
5 Oksenberg JR. et al. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 09 (07) 516-26.
6 Wingerchuk DM. Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mt Sinai J Med 2011; 78 (02) 221-30.
7 Kakalacheva K, Lunemann J. Environmental triggers of multiple sclerosis. FEBS Lett. 2011
8 Ascherio A. et al. Vitamin D and multiple sclerosis. Lancet Neurol 2010; 09 (06) 599-612.
9 Gardener H. et al. Prenatal and perinatal factors and risk of multiple sclerosis. Epidemiology 2009; 20 (04) 611-8.
10 Banwell B. et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011; 10 (05) 436-45.
11 Winkelmann A. et al. Multiple Sklerose und Infektionskrankheiten. Akt Neurol 2011; 38 (07) 339-50.
12 Kamm C, Zettl U. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 2012; 11 (03) 196-202.
13 Zettl UK, Stuve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 2012; 11 (03) 167-73.
14 Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 04 (03) 195-202.
15 Fernandez AM. et al. Microbes, immunity and multiple sclerosis. Curr Immunol Rev 2011; 07 (01) 75-82.
16 Stohlman SA, Hinton DR. Viral induced demyelination. Brain Pathol 2001; 11 (01) 92-106.
17 Ruprecht K. Multiple Sklerose und Epstein-Barr Virus: neue Entwicklungen und Perspektiven. Nervenarzt 2008; 79 (04) 399-407.
18 Ascherio A, Munch A. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000; 11 (02) 220-4.
19 Levin LI. et al. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67 (06) 824-30.
20 Alvarez-Lafuente R. et al. Active human herpesvirus 6 infection in patients with multiple sclerosis. Arch Neurol 2002; 59 (06) 929-33.
21 Enbom M. Human herpesvirus 6 in the pathogenesis of multiple sclerosis. APMIS 2001; 109 (06) 401-11.
22 Altschuler EL. Is JC polyoma virus the cause of ulcerative colitis and multiple sclerosis?. Med Hypotheses 2000; 55 (04) 335-6.
23 Dessau RB, Lisby G, Frederiksen LJ. Coronaviruses in brain tissue from patients with multiple sclerosis. Acta Neuropathol 2001; 101 (06) 601-4.
24 Kriesel JD, Sibley WA. The case for rhinoviruses in the pathogenesis of multiple sclerosis. Mult Scler 2005; 11 (01) 1-4.
25 Perron H. et al. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology 2001; 287 (02) 321-32.
26 Rieger F. et al. New perspectives in multiple sclerosis: retroviral involvement and glial cell death. Pathol Biol (Paris) 2000; 48 (01) 15-24.
27 Rolland A. et al. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis. J Neuroimmunol 2005; 160 (1–2) 195-203.
28 Bergstrom T. Herpesviruses – a rationale for antiviral treatment in multiple sclerosis. Antiviral Res 1999; 41 (01) 1-19.
29 Friedman JE. et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005; 11 (03) 286-95.
30 Ramagopalan SV, Sadovnick AD. Epidemiology of Multiple Sclerosis. Neurologic Clinics 2011; 29 (02) 207-17.
31 Ascherio A, Munger KL. Epstein-barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010; 05 (03) 271-7.
32 Hohlfeld R, Toyka KV. (Multiple sclerosis: updates on pathogenesis and treatment: Report from the 9th MS Symposium held by the German Multiple Sclerosis Society). Nervenarzt 2011; 82 (08) 1026-35.
33 Simon KC. et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010; 74 (17) 1365-71.
34 Sriram S. et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46 (01) 6-14.
35 Contini C. et al. Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Mult Scler 2004; 10 (04) 360-9.
36 Ebringer A. et al. Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch Neurol 2005; 62 (01) 33-6.
37 Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430 6996 257-63.
38 Unterholzner L, Bowie A. The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities. Biochem Pharmacol 2008; 75 (03) 589-602.
39 Gandhi RA. et al. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010; 221 (1–2) 7-14.
40 Carty M, Bowie AG. Evaluating the role of Tolllike receptors in diseases of the central nervous system. Biochem Pharmacol 2011; 81 (07) 825-37.
41 Thaiss CA. et al. The interplay between the innate immune system and the microbiota. Curr Opin Immunol 2014; 26C: 41-48.
42 Bogdanos DP. et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 2013; 12 (07) 726-40.
43 Iebba VM. et al. Gut microbiota and the immune system: an intimate partnership in health and disease. Int J Immunopathol Pharmacol 2012; 25 (04) 823-33.
44 Berer K. et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479 7374 538-41.
45 Manzel A. et al. Role of “Western diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep 2014; 14 (01) 404.
46 Zoetendal EG, de Vos WM. Effect of diet on the intestinal microbiota and its activity. Curr Opin Gastroenterol 2014; 30 (02) 189-95.
47 Khanna S, Tosh PK. A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clin Proc 2014; 89 (01) 107-14.
48 Markle JG. et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 2013; 339 6123 1084-8.
49 Vaarala O. Human intestinal microbiota and type 1 diabetes. Curr Diab Rep 2013; 13 (05) 601-7.
50 Wallberg M, Cooke A. Immune mechanisms in type 1 diabetes. Trends Immunol 2013; 34 (12) 583-91.
51 Proal AD. et al. The human microbiome and autoimmunity. Curr Opin Rheumatol 2013; 25 (02) 234-40.
52 Queiroz-Junior C. et al. Experimental arthritis triggers periodontal disease in mice: involvement of TNF-alpha and the oral Microbiota. J Immunol 2011; 187 (07) 3821-30.
53 Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 2011; 07 (10) 569-78.
54 Patejdl R, Zettl UK. Animal models in neurology: drawbacks and opportunities. Curr Pharm De 2012; 18 (29) 4443-52.
55 Ponsonby L. et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 2005; 293 (04) 463-9.
56 Hernan MA. et al. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 2006; 67 (02) 212-5.
57 Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197-206.
58 Ristori G. et al. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology 2014; 82 (01) 41-8.
59 Winkelmann A. et al. Multiple Sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol 2014; 175 (03) 425-38.
60 The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45 (07) 1277-85.
61 Goodin D. et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 2012; 78 (17) 1315-22.
62 Johnson KP. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45 (07) 1268-76.
63 Johnson KP. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50 (03) 701-8.
64 Fensterl V, Sen GC. Interferons and viral infections. Biofactors 2009; 35 (01) 14-20.
65 Riminton DS. et al. Managing the risks of immunosuppression. Curr Opin Neurol 2011; 24 (03) 217-23.
66 Biogen. Tysabri (web page). 2014 02 March 2014 Available from: www.Tysabri.de
67 Vermersch P. et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76 (20) 1697-704.
68 Dahlhaus S. et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013; 84 (10) 1068-74.
69 Bloomgren G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366 (20) 1870-80.
70 Sorensen PS. et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18 (02) 143-52.
71 Schwab N. et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81 (10) 865-71.
72 Freedman MS. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-beta therapy. Eur J Neurol 2014; 21 (03) 377-e20.
73 Weber T. Progressive multifocal leukoencephalo-pathy. Neurol Clin 2008; 26 (03) 833-54.
74 Cohen JA. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362 (05) 402-15.
75 Winkelmann A. et al. Fingolimod treatment for multiple sclerosis patients What do we do with varicella?. Ann Neurol 2011; 70 (04) 673-4.
76 Uhthoff W. Untersuchungen über die bei der multiplen Herdsklerose vorkonimenden Augen-störungen. Archiv für Psychiatrie und Nervenkrankheiten 1890; 21 (02) 305-410.
77 Guthrie TC, Nelson DA. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J Neurol Sci 1995; 129 (01) 1-8.
78 Oh J, O’Connor P W. Teriflunomide for the treatment of multiple sclerosis. Semin Neurol 2013; 33 (01) 45-55.
79 Wiese MD. et al. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol 2013; 09 (08) 1025-35.
80 O’Connor PW. et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66 (06) 894-900.
81 O’Connor P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365 (14) 1293-303.
82 Confavreux C. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13 (03) 247-56.
83 Yoo HG. et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol 2013; 23 (04) 709-15.
84 Gold R. et al. Placebo-controlled phase 3 study of oral G-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367 (12) 1098-107.
85 Fox RJ. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367 (12) 1087-97.
86 Sweetser MT. et al. Manufacturer’s response to case reports of PML. N Engl J Med 2013; 368 (17) 1659-61.
87 van Oosten BW. et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368 (17) 1658-9.
88 Kothary N. et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65 (03) 546-51.
89 Hill-Cawthorne GA. et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83 (03) 298-304.
90 Klotz L. et al. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 2012; 142 (01) 25-30.
91 Cohen JA. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 2012; 380 9856 1819-28.
92 Coles AJ. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380 9856 1829-39.
93 De Keyser J. et al. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998; 159 (01) 51-3.
94 Loebermann M. et al. Immunization in the adult immunocompromised host. Autoimmun Rev 2012; 11 (03) 212-8.
95 Loebermann M. et al. Impfen und Multiple Sklerose. Nervenarzt 2010; 81 (02) 181-93.
96 Loebermann M. et al. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 2011; 08 (03) 143-51.
97 Correale J. et al. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006; 67 (04) 652-9.
98 Boršo D. et al. Impfen bei Immundefekten oder medikamentöser Immunsuppression. Dtsch Med Wochenschr 2013; 138 (04) 119-125.
99 De Keyser J. Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection 1998; 26 (05) 319.